This Article Full Text Full Text (PDF) All Versions of this Article: 45/3/341    most recent 01.HYP.0000156878.17006.02v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Booz, G. W. Search for Related Content PubMed PubMed Citation Articles by Booz, G. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Structure Other myocardial biology Hypertrophy Remodeling Oxidant stress Apoptosis

(Hypertension. 2005;45:341.)
© 2005 American Heart Association, Inc.

Hypertension Highlights

Putting the Brakes on Cardiac Hypertrophy

Exploiting the NO–cGMP Counter-Regulatory System

From the Cardiovascular Research Institute, the Texas A&M University System Health Science Center, College of Medicine, Temple, Tex.

Correspondence to George W. Booz, PhD, FAHA, Cardiovascular Research Institute, Texas A&M College of Medicine, 1901 South 1^st Street, Bldg 205, Temple, TX 76504. E-mail gbooz{at}medicine.tamhsc.edu

Abstract

We know a great deal about the receptors and signaling pathways in cardiomyocytes that contribute to hypertrophic growth. Although drugs that target them have proven effective in substantially reducing left ventricular hypertrophy and associated mortality, cardiovascular disease remains the leading cause of death in the West. Another approach may rest with exploiting naturally occurring regulators of maladaptive cardiac hypertrophy that have been identified in the past few years. These endogenous negative regulators can be grouped, for the most part, into those constitutively active but whose activity is decreased by hypertrophic stimulation, and those with little or no baseline activity that are activated by hypertrophic stimulation. Spanning both groups are 4 systems that converge on cyclic guanosine 3', 5'-monophosphate (cGMP) generation, namely natriuretic peptides (ANP and BNP), kinins, nitric oxide (NO), and the angiotensin II type 2 receptor (AT₂). Although holding promise as a means for restricting hypertrophy, each of these signaling molecules has certain limitations that need to be overcome. What follows is an overview of research over the past 2 years, much of it published in Hypertension, which has dealt with the antihypertrophic action of this particular group of endogenous signaling molecules. Understanding the function and regulation of the antihypertrophic NO–cGMP system offers the promise of novel therapeutic strategies for treating cardiac hypertrophy and heart failure.

Key Words: adrenergic antagonists • angiotensin II • kinins • natriuretic peptides • nitric oxide synthase • statins

This article has been cited by other articles:

				X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al. Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281. [Abstract] [Full Text] [PDF]

				M. Zaccolo and M. A. Movsesian cAMP and cGMP Signaling Cross-Talk: Role of Phosphodiesterases and Implications for Cardiac Pathophysiology Circ. Res., June 8, 2007; 100(11): 1569 - 1578. [Abstract] [Full Text] [PDF]

				D. Juric, P. Wojciechowski, D. K. Das, and T. Netticadan Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2138 - H2143. [Abstract] [Full Text] [PDF]

				E. Takimoto, D. Belardi, C. G. Tocchetti, S. Vahebi, G. Cormaci, E. A. Ketner, A. L. Moens, H. C. Champion, and D. A. Kass Compartmentalization of Cardiac {beta}-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 Circulation, April 24, 2007; 115(16): 2159 - 2167. [Abstract] [Full Text] [PDF]

				C. Cerutti, M. Kurdi, G. Bricca, W. Hodroj, C. Paultre, J. Randon, and M.-P. Gustin Transcriptional alterations in the left ventricle of three hypertensive rat models Physiol Genomics, November 21, 2006; 27(3): 295 - 308. [Abstract] [Full Text] [PDF]

				R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]

				G. W. Booz Impact of T Lymphocytes on Cardiac Remodeling in Hypertension: More Questions Than Answers Hypertension, July 1, 2006; 48(1): 31 - 32. [Full Text] [PDF]

				E. Souzeau, B. Llamas, S. Belanger, S. Picard, and C. F. Deschepper A Genetic Locus Accentuates the Effect of Volume Overload on Adverse Left Ventricular Remodeling in Male and Female Rats Hypertension, January 1, 2006; 47(1): 128 - 133. [Abstract] [Full Text] [PDF]